Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ELREXFIO 40 MG/ML SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ELREXFIO 40 MG/ML SOLUCION INYECTABLE

Approved

STANDARD

ELREXFIO 40 MG/ML SOLUCION INYECTABLE

Pfizer Europe Ma Eeig🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 18, 2023
Approval ID: 818733f0789a8469
Company: Pfizer Europe Ma Eeig
Type: Standard

Approval Details

Approval Id: 818733f0789a8469
Drug Cima Aemps Name: ELREXFIO 40 MG/ML SOLUCION INYECTABLE
Register Number: 1231770001
Holder Company Name: Pfizer Europe Ma Eeig
Marketing Company Name: Pfizer S.L.
Holder Company Detail Path: /organization/pfizer-europe-ma-eeig
Authorization Date: 2023-12-18
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 40 mg/ml
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Pfizer Europe Ma Eeig
Company Detail Path: /organization/pfizer-europe-ma-eeig

Company Information

Pharmaceutical Company Name: Pfizer Europe MA EEIG
Country Name: United Kingdom

Active Ingredients

ELRANATAMAB

40 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 18, 2023

Approval ID

818733f0789a8469

Type

Standard

Back to CIMA-AEMPS Approvals